Carboplatin Niosomal Nanoplatform for Potentiated Chemotherapy.

Autor: Alavi SE; Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Microbiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran., Raza A; School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia., Koohi Moftakhari Esfahani M; Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Microbiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran., Akbarzadeh A; Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran., Abdollahi SH; Department of Microbiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran., Ebrahimi Shahmabadi H; Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Microbiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Electronic address: ebrahimi@rums.ac.ir.
Jazyk: angličtina
Zdroj: Journal of pharmaceutical sciences [J Pharm Sci] 2022 Nov; Vol. 111 (11), pp. 3029-3037. Date of Electronic Publication: 2022 Jun 05.
DOI: 10.1016/j.xphs.2022.06.002
Abstrakt: This study aimed to characterize a stable nano-niosome formulation, which could reduce the adverse effects of carboplatin (CB) and improve its therapeutic efficacy in the treatment of breast cancer. For this purpose, CB-loaded polyethylene glycol (PEG)ylated niosome nanoparticles (PEG-NS-CB) were synthesized using the reverse-phase evaporation method. PEG-NS-CB (226.0 ± 10.6 nm) could release CB in a controlled manner and, compared to CB and CB-loaded non-PEGylated niosome (NS-CB), caused higher cytotoxicity effects against mouse breast cancer 4T1 cells (IC 50 : 83.4, 26.6, and 22.5 µM for CB, NS-CB, and PEG-NS-CB, respectively). Also, PEG-NS-CB demonstrated higher stability, in which its profile of drug release, cytotoxicity, and LE% did not change significantly three months after preparation compared to those at the production time. In addition, the in vivo results demonstrated that PEG-NS-CB caused higher therapeutic (the number of alive mice: 12, 15, and 17 out of 20 in CB, NS-CB, and PEG-NS-CB receiver groups, respectively) and less toxicity effects (weight loss of 17, 12.5, and 10% in CB, NS-CB, and PEG-NS-CB receiver groups, respectively), compared to NS-CB and CB in breast cancer-bearing mice. Overall, the results of this study suggest that PEG-NS-CB could be a promising formulation for the treatment of breast cancer.
Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest.
(Copyright © 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: